LivaNova (NASDAQ:LIVN) Updates FY25 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $3.65-3.75 for the period, compared to the consensus estimate of $3.66. The company issued revenue guidance of ~$1.316-1.329 billion, compared to the consensus revenue estimate of $1.33 billion. LivaNova also updated its FY 2025 guidance to 3.650-3.750 EPS.

LivaNova Stock Down 0.9 %

LIVN traded down $0.36 during trading on Thursday, hitting $41.09. The company had a trading volume of 334,431 shares, compared to its average volume of 562,819. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $47.65 and its 200 day moving average price is $49.56. The company has a market capitalization of $2.23 billion, a PE ratio of 97.72 and a beta of 1.00. LivaNova has a one year low of $40.37 and a one year high of $64.47.

Analyst Ratings Changes

LIVN has been the topic of several analyst reports. Needham & Company LLC cut their price target on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday. Robert W. Baird lifted their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Stifel Nicolaus reduced their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, Mizuho cut their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $64.20.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.